AMRSQ — Amyris Share Price
0.000.00%
Last trade - 00:00- $0.55m
- $946.61m
- $269.85m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -301.58% | ||
| Return on Equity | n/a | ||
| Operating Margin | -234.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 63.6 | 152.56 | 173.14 | 341.82 | 269.85 | 487.9 | 530.3 | 16.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Amyris, Inc. is a synthetic biotechnology company. The component of the Company is derived from marketing and selling Clean Beauty, Personal Care, and Health & Wellness consumer products through its direct-to-consumer e-commerce platforms and a growing network of retail partners. The Company’s sustainable ingredients are sold in bulk to industrial leaders who serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets. The ingredients and consumer products it produces by its Lab-to-Market technology platform. The Company leverages machine learning, robotics, and artificial intelligence, which enables its technology platform to rapidly bring new market at commercial scale. The Lab-to-Market technology platform utilizes optimized and automated molecular biology, analytical, and process development tools combined with machine learning algorithms and statistical models to transform the way microbes metabolize sugars.
Directors
- Geoffrey Duyk NEC (61)
- John Melo CEO (55)
- Han Kieftenbeld CFO (55)
- Eduardo Alvarez COO (57)
- Nicole Kelsey GCN (54)
- Francisco Costa OTH
- Philip Eykerman DRC (52)
- Ryan Panchadsaram DRC
- John Doerr IND (69)
- Ana Dutra IND (56)
- Frank Kung IND (72)
- James Mccann IND (70)
- Steven Mills IND (65)
- Lisa Qi IND (49)
- Julie Washington IND (55)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- April 15th, 2010
- Public Since
- September 28th, 2010
- No. of Shareholders
- 166
- No. of Employees
- 1,598
- Sector
- Chemicals
- Industry
- Basic Materials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 369,385,614
- Address
- 5885 Hollis St Ste 100, EMERYVILLE, 94608-2405
- Web
- https://www.amyris.com/
- Phone
- +1 5104500761
- Auditors
- Macias Gini and O Connell, LLP
Upcoming Events for AMRSQ
Amyris Inc Annual Shareholders Meeting
Similar to AMRSQ
Advanced Container Technologies
Pink Sheets on Nasdaq
Alkane
Pink Sheets on Nasdaq
Angstrom Technologies
Pink Sheets on Nasdaq
Asia Carbon Industries
Pink Sheets on Nasdaq
BioLargo
Pink Sheets on Nasdaq
FAQ
What is the Amyris share price?
As of Today at 19:02 UTC, shares in Amyris are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Amyris share price performed this year?
Shares in Amyris last closed at $0.00 and the price had moved by -99.82% over the past 365 days. In terms of relative price strength the Amyris share price has underperformed the S&P500 Index by -99.84% over the past year.
What are the analyst and broker recommendations for Amyris?
The overall consensus recommendation for Amyris is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Amyris dividend yield?
Amyris does not currently pay a dividend.
Does Amyris pay a dividend?
Amyris does not currently pay a dividend.
When does Amyris next pay dividends?
Amyris does not currently pay a dividend.
How do I buy Amyris shares?
To buy shares in Amyris you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Amyris?
As of the previous close price of $0.00, shares in Amyris had a market capitalisation of $0.55m.
Where are Amyris shares listed?
Here are the trading details for Amyris:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AMRSQ
What kind of share is Amyris?
Based on an overall assessment of its quality, value and momentum Amyris is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Amyris share price forecast for 2024?
The analyst consensus target price for shares in Amyris is $0.75. That is 49900% above the last closing price of $0.00.
Analysts covering Amyris currently have a consensus Earnings Per Share (EPS) forecast of -$0.68 for the next financial year.
What is the trend in the Amyris share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amyris. Over the past six months, its share price has underperformed the S&P500 Index by -81.53%.
As of the last closing price of $0.00, shares in Amyris were trading -98.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Amyris PE Ratio?
The Amyris PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Amyris?
Amyris' management team is headed by:
- Geoffrey Duyk - NEC
- John Melo - CEO
- Han Kieftenbeld - CFO
- Eduardo Alvarez - COO
- Nicole Kelsey - GCN
- Francisco Costa - OTH
- Philip Eykerman - DRC
- Ryan Panchadsaram - DRC
- John Doerr - IND
- Ana Dutra - IND
- Frank Kung - IND
- James Mccann - IND
- Steven Mills - IND
- Lisa Qi - IND
- Julie Washington - IND